Welcome to our dedicated page for MapLight Therapeutics SEC filings (Ticker: MPLT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page is intended to provide access to U.S. Securities and Exchange Commission (SEC) filings for MapLight Therapeutics, Inc. (Nasdaq: MPLT), a clinical-stage biopharmaceutical company focused on central nervous system disorders. While no specific filings are listed in the available data here, as a Nasdaq-listed issuer MapLight has described an initial public offering and a concurrent private placement conducted under an effective registration statement filed with the SEC.
In general, SEC filings for a company like MapLight can include annual reports on Form 10-K, quarterly reports on Form 10-Q, and current reports on Form 8-K that describe material events such as clinical trial updates, financing transactions, or significant collaborations. Registration statements and prospectuses related to offerings, such as the IPO MapLight has referenced, also form part of the company’s regulatory record.
For a clinical-stage biopharmaceutical company, these filings typically discuss the status of product candidates like ML-007C-MA, ML-004, ML-021 and ML-009, outline clinical development plans, and describe risk factors related to central nervous system drug development. They may also provide details on research and development expenses, cash resources from offerings and private placements, and other financial information.
Stock Titan’s platform enhances access to such documents by pairing real-time updates from the SEC’s EDGAR system with AI-powered summaries. These tools are designed to help readers interpret lengthy filings, highlight key topics such as clinical trial disclosures, financing terms, and collaboration agreements, and locate information about insider transactions reported on Form 4 when available.
Anatol Kreitzer filed a notice covering a planned sale of 36,284 shares of MapLight voting common stock of MapLight Therapeutics, Inc., to be sold through Morgan Stanley Smith Barney LLC on or about July 15, 2026 on Nasdaq, with an aggregate market value of $1,375,526.00.
The notice also lists prior sales of MapLight voting common stock in the past three months: 3,316 shares for $88,239.00 on April 15, 2026, and 45,422 shares for $1,347,066.00 on April 27, 2026. Shares outstanding are reported as 42,618,165.
MapLight Therapeutics, Inc. has a notice covering the proposed sale of 36979 shares of MapLight voting common stock through Morgan Stanley Smith Barney LLC, with an aggregate market value of 1401874.00 and an approximate sale date of 07/15/2026. The shares are associated with a restricted stock unit settlement. The notice also lists prior April 2026 sales of MapLight voting common stock, including transactions for 3590, 51900 and 17935 shares on 04/15/2026, 04/27/2026 and 04/28/2026, respectively, with corresponding cash proceeds disclosed.
MapLight Therapeutics, Inc. reports that Anatol Kreitzer has filed a notice to sell up to 33,605 shares of MapLight voting common stock through Morgan Stanley Smith Barney LLC, with an aggregate market value of 1273966.00, around July 15, 2026 on Nasdaq.
Shares of this class outstanding were 42,618,165. During the past three months, Kreitzer sold 3,316 shares for 88239.00 on April 15, 2026 and 45,422 shares for 1347066.00 on April 27, 2026.
Maplight Therapeutics, Inc. has a planned sale of 48,158 common shares of its stock through Jefferies LLC, with an indicated sale date of July 15, 2026 on NASDAQ. The shares have an aggregate market value of $1,825,669.78, while 42,620,000 shares are outstanding. The seller, Erin Pennock Foff, acquired Maplight shares via restricted stock unit grants on several dates and has already sold multiple blocks of shares between April 15 and May 7, 2026, including 24,052 shares on May 6, 2026 for $691,814.17.
Maplight Therapeutics, Inc. shareholder Christopher Kroeger has filed to sell up to 152,230 common shares through broker Jefferies LLC, with an aggregate market value of 5,771,039.30, on or after July 15, 2026 on the NASDAQ market. The notice lists 42,620,000 common shares outstanding. It also details the acquisition history of the shares, including several Restricted Stock Unit grants from 2023 to 2025. In addition, it itemizes prior sales by Kroeger over the past three months, including a sale of 118,235 shares on May 18, 2026 for 3,215,511.97 and several smaller trades in April and May 2026.
Maplight Therapeutics, Inc. is the issuer in a notice that lists its common stock alongside Jefferies LLC, with figures of 16,508 and 625,818.28 reported together with a date of 07/15/2026 and a reference to Nasdaq.
The disclosure links several Restricted Stock Unit Grant entries for Maplight Therapeutics, Inc. to quantities of 1,668 (07/30/2023), 853 (11/09/2023), 3,012 (05/02/2024) and 27,484 (07/18/2025). It also shows Kris Hanson as having sold common stock during the past three months, including two entries of 13,917 with associated figures up to 419,224.02.
James Lillie plans to sell up to 18,835 shares of MapLight Therapeutics, Inc. common stock through broker Jefferies LLC. The planned sale has an aggregate market value of $714,034.85, with MapLight reporting 42,620,000 common shares outstanding and an approximate sale date of July 15, 2026.
The shares come from several Restricted Stock Unit grants made between 2023 and 2025. Lillie has also sold MapLight shares over the prior three months, including 24,811 shares for $713,661.87 on May 6, 2026, along with additional smaller transactions in April and May 2026.
MapLight Therapeutics director Troy Cox received new equity awards as part of non-employee director compensation. He was granted 7,864 restricted stock units, each representing one share of voting common stock. These RSUs vest in three equal annual installments beginning on June 23, 2027, contingent on his continued service.
He was also granted a stock option covering 29,804 shares of voting common stock at an exercise price of $28.64 per share, vesting on the same three-year schedule starting June 23, 2027. After these grants, his reported direct holdings include 7,864 shares from RSUs and 29,804 underlying option shares.
MapLight Therapeutics director Babler Martin received new equity awards as part of non-employee director compensation. He was granted 7,864 restricted stock units and a stock option for 29,804 shares of Voting Common Stock at an exercise price of $28.64 per share.
The RSUs and option were granted under the 2025 Equity Incentive Plan and will vest in three equal annual installments beginning on June 23, 2027, contingent on his continued service. Following these grants, Martin holds 7,864 shares of Voting Common Stock directly and the newly granted option covering 29,804 underlying shares.